Immix Biopharma (IMMX) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, gaining 265.7% versus a loss of 39.0%. Inventiva S.A. American Depository Shares is the larger company by market cap ($784.3 million vs $770.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMX | IVA |
|---|---|---|
| Share price | $9.29 | $3.32 |
| Market cap | $770.17M | $784.25M |
| 1-day change | -2.11% | -1.34% |
| YTD return | +77.63% | -27.63% |
| 1-year return | +265.75% | -39.04% |
| 5-year return | — | -74.89% |
| EPS (TTM) | $-0.88 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.10 | $7.98 |
| 52-week low | $2.31 | $3.11 |
| Distance from 52-week high | -38.48% | -58.41% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +161.57% | +357.83% |
| Average volume | 1.65M | 1.38M |
| Shares outstanding | 82.90M | 236.22M |
| Employees | 21 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed IVA by 304.8 percentage points over the past year.
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
IMMX vs IVA FAQ
Which is bigger, Immix Biopharma or Inventiva S.A. American Depository Shares?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $784.25M compared with $770.17M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, IMMX or IVA?
IMMX returned +265.75% over the past 12 months, compared with -39.04% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Immix Biopharma and Inventiva S.A. American Depository Shares in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.